Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 448,000 shares, a growth of 2,348.1% from the October 15th total of 18,300 shares. Based on an average daily trading volume, of 598,100 shares, the days-to-cover ratio is presently 0.7 days. Approximately 24.9% of the company’s shares are sold short.

Lixte Biotechnology Stock Performance

Shares of NASDAQ:LIXT traded down $0.04 on Thursday, hitting $1.60. 18,680 shares of the company’s stock were exchanged, compared to its average volume of 349,342. The firm’s 50-day moving average is $1.86 and its 200 day moving average is $2.17. The company has a market capitalization of $3.60 million, a PE ratio of -0.95 and a beta of -0.17. Lixte Biotechnology has a 1-year low of $1.31 and a 1-year high of $4.42.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.